Cancer cells develop strong anti-apoptotic signaling pathways and therefore escape many therapeutic regimens. Recognizing this feature of cancer cells, we have focused on two approaches: dis-arming the cancer cell from its anti-apoptotic weaponry [1, 2] and applying strategies aimed at enhancing pro-apoptotic signa-ling pathways selectively in the cancer cell [3]. The first goal has been achieved by developing highly selective Aktstatins [1, 2] that inhibit PKB 100 times better than PKA or PKC.
